Poland· PL-100129848
Rebetol
A ribavirin product containing ribavirinum, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Ribavirin is registered in 10 of 19 countries.
Countries holding a registration under ATC J05AP01 (ribavirin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Ribavirin · ATC J05AP01
10 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Germany
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Ribavirinum
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Poland (PL)
- ATC code
- J05AP01
- ATC class
- Ribavirin
- Defined daily dose
- 6 g, Inhal
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990011162
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
143 interactions on record for ribavirin.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ribavirin · interactions on record
143 records
- 4 severe
- 4 moderate
- 135 info
Most severe, free to view
- MercaptopurineL01BB02severe
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
- AzathioprineL04AX01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ribavirin in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRebetol 40 mg/mlMerck Sharp & Dohme
- SpainREBETOL 40 MG/ML SOLUCION ORALMerck Sharp & Dohme B.V.
- FinlandRebetolMerck Sharp & Dohme B.V.
- FranceREBETOL 40 mg/ml, solution buvableMERCK SHARP & DOHME (PAYS-BAS)
- United StatesRibavirinCameron Pharmaceuticals
- United KingdomCopegus 200mg tabletsRoche Products Ltd
- NorwayRibavirin aurobindoAurobindo
- SwedenRibavirin Mylan 200 mg Kapsel, hårdMylan S.A.S.
Authorised across Europe · EMA
The same active substance is authorised in 8 EEA countries. Names it is sold under:
- Cyprus · Ribavirin Aurobindo
- Germany · Ribavirin Ratiopharm
- Spain · Ribavirina Normon
- France · Ribavirine Pharmadev, Ribavirine Skyepharma
- United Kingdom (Northern Ireland) · Ribavirin Milpharm
- Italy · Ribavirina Aurobindo
- Netherlands · Ribavirine Ratiopharm
- Portugal · Ribavirina Aurobindo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0a01cbbc-56eb-4ac1-b1b7-dff880addd70 GET /v1/drugs/0a01cbbc-56eb-4ac1-b1b7-dff880addd70?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór doustny",
"source": "urpl",
"strength": "40 mg/ml",
"packaging": "05909990011162 ¦ Rpz ¦ EU/1/99/107/004 ¦ 13865\n1 butelka 100 ml",
"substance": "Ribavirinum 40 mg/ml",
"common_name": "Ribavirinum",
"pl_product_id": "100129848",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": "2023-10-18"
}See everything about ribavirin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.